These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
414 related articles for article (PubMed ID: 35917335)
1. Development of Fibroblast Activation Protein Inhibitor-Based Dimeric Radiotracers with Improved Tumor Retention and Antitumor Efficacy. Zhao L; Chen J; Pang Y; Fang J; Fu K; Meng L; Zhang X; Guo Z; Wu H; Sun L; Su G; Lin Q; Chen H Mol Pharm; 2022 Oct; 19(10):3640-3651. PubMed ID: 35917335 [TBL] [Abstract][Full Text] [Related]
2. Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of Zhao L; Niu B; Fang J; Pang Y; Li S; Xie C; Sun L; Zhang X; Guo Z; Lin Q; Chen H J Nucl Med; 2022 Jun; 63(6):862-868. PubMed ID: 34556528 [TBL] [Abstract][Full Text] [Related]
3. Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy. Pang Y; Zhao L; Fang J; Chen J; Meng L; Sun L; Wu H; Guo Z; Lin Q; Chen H J Nucl Med; 2023 Sep; 64(9):1449-1455. PubMed ID: 37321827 [TBL] [Abstract][Full Text] [Related]
4. Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the Läppchen T; Bilinska A; Pilatis E; Menéndez E; Imlimthan S; Moon ES; Afshar-Oromieh A; Rösch F; Rominger A; Gourni E Molecules; 2024 Jun; 29(13):. PubMed ID: 38999044 [TBL] [Abstract][Full Text] [Related]
5. A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy. Yang T; Peng L; Qiu J; He X; Zhang D; Wu R; Liu J; Zhang X; Zha Z Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2331-2341. PubMed ID: 36864362 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and Preclinical Evaluation of a Novel FAPI-04 Dimer for Cancer Theranostics. Zhong X; Guo J; Han X; Wu W; Yang R; Zhang J; Shao G Mol Pharm; 2023 May; 20(5):2402-2414. PubMed ID: 37015025 [TBL] [Abstract][Full Text] [Related]
7. Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy. Xu M; Zhang P; Ding J; Chen J; Huo L; Liu Z J Nucl Med; 2022 Jun; 63(6):952-958. PubMed ID: 34593598 [TBL] [Abstract][Full Text] [Related]
8. Preclinical Evaluation and a Pilot Clinical Positron Emission Tomography Imaging Study of [ Du X; Gu B; Wang X; Wang X; Ji M; Zhang J; He S; Xu X; Yang Z; Song S Mol Pharm; 2024 Feb; 21(2):904-915. PubMed ID: 38179677 [TBL] [Abstract][Full Text] [Related]
9. Development and Evaluation of DOTA-FAPI-Maleimide as a Novel Radiotracer for Tumor Theranostic with Extended Circulation. Feng L; Hu W; Zeng X; Wei Z; Long Y; Li M; Sun S; Guo Z; Lan X; Zhang X; Zhuang R; Jiang D Mol Pharm; 2024 Sep; 21(9):4386-4394. PubMed ID: 39046432 [TBL] [Abstract][Full Text] [Related]
10. Fibroblast Activation Protein Targeting Probe with Gly-Pro Sequence for PET of Glioblastoma. Lai C; Cao R; Li R; He C; Wang X; Shi H; Qu C; Qian K; Song S; Chen WH; Cheng Z Mol Pharm; 2023 Aug; 20(8):4120-4128. PubMed ID: 37487027 [TBL] [Abstract][Full Text] [Related]
11. [ Shang Y; Zhang G; Yao X; Lai C; Wang F; Zeng B; Liu E; Yuan H; Cheng Z; Jiang L Mol Imaging Biol; 2024 Aug; 26(4):729-737. PubMed ID: 38987449 [TBL] [Abstract][Full Text] [Related]
12. Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-α (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors. Poplawski SE; Hallett RM; Dornan MH; Novakowski KE; Pan S; Belanger AP; Nguyen QD; Wu W; Felten AE; Liu Y; Ahn SH; Hergott VS; Jones B; Lai JH; McCann JAB; Bachovchin WW J Nucl Med; 2024 Jan; 65(1):100-108. PubMed ID: 38050111 [TBL] [Abstract][Full Text] [Related]